Reported Sunday, JELMYTO Demonstrates Remarkable 86% Recurrence-Free Survival Rate At 24 Months For All Studied Patient And Disease Characteristics
Reported Sunday, JELMYTO Demonstrates Remarkable 86% Recurrence-Free Survival Rate At 24 Months For All Studied Patient And Disease Characteristics
週日報道，JELMYTO顯示，所有研究的患者和疾病特徵在24個月內無復發存活率均爲86％
- There Were No Differences in RFS Regarding Usage for Chemoablation or Post-Endoscopic Ablation, Tumor Size, Multifocality, or Tumor Location
- RFS Was 100% in Patients who Received Maintenance therapy vs 61% for Patients Who Did Not Receive Maintenance Therapy
- "The 86% recurrence-free survival rate at the 24-month mark among low-grade UTUC patients (n=53) exhibited a favorable response to the initial induction of this new treatment," said Adam Feldman, M.D., M.P.H., Urologic Oncologist in the Department of Urology at Massachusetts General Hospital, and Director of the Combined Harvard Urologic Oncology Fellowship. "Notably, there seems to be no discernible difference in disease recurrence based on tumor characteristics or timing of administration, including primary chemoablation or post-endoscopic ablation. These results offer additional evidence for the clinical utility of JELMYTO and may also offer hope for improved long-term outcomes for our patients."
- 在化療消融或內窺鏡消融術的用法、腫瘤大小、多焦點或腫瘤位置方面，RFS沒有差異
- 接受維持治療的患者的RFS爲100％，而未接受維持治療的患者的RFS爲61％
- 麻省總醫院泌尿外科腫瘤科醫生、哈佛泌尿外科腫瘤聯合獎學金主任亞當·費爾德曼說：“低度UTUC患者（n=53）在24個月大關時無復發存活率爲86％（n=53）對這種新療法的初始引入表現出良好的反應。”“值得注意的是，根據腫瘤特徵或給藥時間，包括原發性化療或內窺鏡後消融術，疾病復發似乎沒有明顯的區別。這些結果爲JELMYTO的臨床用途提供了更多證據，也可能爲我們的患者帶來改善長期療效的希望。”
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。